Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Merlin (NF2)

  • Mateus Mota
  • Rajeev S. Samant
  • Lalita A. ShevdeEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101780


Historical Background

Neurofibromatosis type 2 (NF2) is a tumor suppressor gene that when deleted or mutated causes a disorder with the same name. This condition is primarily characterized by benign tumors of the nervous system such as bilateral vestibular schwannomas – originating from Schwann cell – in addition to meningiomas and ependymomas, which arise from cells that make up the membrane surrounding the brain and spinal cord and from the ependyma, a tissue of the central nervous system, respectively (Petrilli and Fernandez-Valle 2016). The incidence ratio of this dominantly inherited disease is 1:25,000, and 50–60% of cases are caused by de novo mutations with somatic mosaicism. NF2somatic mutations have also been found in...

This is a preview of subscription content, log in to check access.



NIH R01CA138850 and Breast Cancer Research Foundation of Alabama (BCRFA) grants to L.A.S.


  1. Ammoun S, Hanemann CO. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol. 2011;7(7):392–9.CrossRefPubMedGoogle Scholar
  2. Bianchi AB, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A. 1995;92(24):10854–8.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Cooper J, Giancotti FG. Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett. 2014;588(16):2743–52.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Curto M, et al. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol. 2007;177(5):893–903.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Horiguchi A, et al. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells. Prostate. 2008;68(9):975–84.CrossRefPubMedGoogle Scholar
  6. Houshmandi SS, et al. The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol. 2009;29(6):1472–86.CrossRefPubMedGoogle Scholar
  7. James MF, et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009;29(15):4250–61.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Lallemand D, et al. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 2003;17(9):1090–100.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Lau YK, et al. Merlin is a potent inhibitor of glioma growth. Cancer Res. 2008;68(14):5733–42.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Li W, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell. 2010;140(4):477–90.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Lopez-Lago MA, et al. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol. 2009;29(15):4235–49.PubMedPubMedCentralCrossRefGoogle Scholar
  12. McClatchey AI, Giovannini M. Membrane organization and tumorigenesis – the NF2 tumor suppressor, Merlin. Genes Dev. 2005;19(19):2265–77.CrossRefPubMedGoogle Scholar
  13. Morrison H, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 2001;15(8):968–80.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Morrow KA, et al. Loss of tumor suppressor Merlin results in aberrant activation of Wnt/beta-catenin signaling in cancer. Oncotarget. 2016;7(14):17991–8005.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Morrow KA, et al. Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. J Biol Chem. 2011;286(46):40376–85.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Murray LB, et al. Merlin is a negative regulator of human melanoma growth. PLoS One. 2012;7(8):e43295.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Okada T, et al. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol. 2005;171(2):361–71.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Petrilli AM, Fernandez-Valle C. Role of Merlin/NF2 inactivation in tumor biology. Oncogene. 2016;35(5):537–48.CrossRefPubMedGoogle Scholar
  19. Poulikakos PI, et al. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene. 2006;25(44):5960–8.CrossRefPubMedGoogle Scholar
  20. Rong R, et al. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A. 2004;101(52):18200–5.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Sekido Y, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55(6):1227–31.PubMedGoogle Scholar
  22. Shah NR, et al. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol. 2014;134(1):104–11.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Shapiro IM, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6(237):237ra268–8.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Shaw RJ, et al. Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J Biol Chem. 1998;273(13):7757–64.CrossRefPubMedGoogle Scholar
  25. Thurneysen C, et al. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer. 2009;64(2):140–7.CrossRefPubMedGoogle Scholar
  26. Zhang N, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell. 2010;19(1):27–38.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Mateus Mota
    • 1
  • Rajeev S. Samant
    • 2
    • 3
  • Lalita A. Shevde
    • 1
    Email author
  1. 1.Division of Molecular and Cellular Pathology, Department of Pathology and Comprehensive Cancer CenterUniversity of Alabama at Birmingham, Wallace Tumor InstituteBirminghamUSA
  2. 2.Division of Molecular and Cellular Pathology, Department of PathologyUniversity of Alabama at Birmingham, Wallace Tumor InstituteBirminghamUSA
  3. 3.Department of Pathology and Comprehensive Cancer CenterThe University of AlabamaBirminghamUSA